Positive News SentimentPositive NewsNASDAQ:RCEL AVITA Medical (RCEL) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free RCEL Stock Alerts $16.03 -0.47 (-2.85%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$15.82▼$16.6550-Day Range$13.91▼$18.3152-Week Range$9.16▼$21.70Volume126,171 shsAverage Volume167,014 shsMarket Capitalization$412.13 millionP/E RatioN/ADividend YieldN/APrice Target$27.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AVITA Medical alerts: Email Address AVITA Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside73.4% Upside$27.80 Price TargetShort InterestHealthy2.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.15) to ($0.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.82 out of 5 starsMedical Sector685th out of 938 stocksSurgical & Medical Instruments Industry69th out of 94 stocks 3.5 Analyst's Opinion Consensus RatingAVITA Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.80, AVITA Medical has a forecasted upside of 73.4% from its current price of $16.03.Amount of Analyst CoverageAVITA Medical has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.49% of the float of AVITA Medical has been sold short.Short Interest Ratio / Days to CoverAVITA Medical has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AVITA Medical has recently increased by 2.14%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAVITA Medical does not currently pay a dividend.Dividend GrowthAVITA Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RCEL. Previous Next 2.7 News and Social Media Coverage News SentimentAVITA Medical has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for AVITA Medical this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for RCEL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added AVITA Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AVITA Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of AVITA Medical is held by insiders.Percentage Held by InstitutionsOnly 27.66% of the stock of AVITA Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AVITA Medical are expected to grow in the coming year, from ($1.15) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AVITA Medical is -11.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AVITA Medical is -11.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAVITA Medical has a P/B Ratio of 8.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About AVITA Medical Stock (NASDAQ:RCEL)AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.Read More RCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCEL Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comRCEL Oct 2024 17.500 putMarch 16, 2024 | finance.yahoo.comRCEL Apr 2024 22.500 putMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 5, 2024 | seekingalpha.comAVITA Medical: Unconvincing Growth Amid Fierce Competition In The Burn Care SectorFebruary 29, 2024 | finance.yahoo.comAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA SupplementFebruary 29, 2024 | globenewswire.comAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA SupplementFebruary 29, 2024 | globenewswire.comAVITA Medical to Present at TD Cowen 44th Annual Health Care ConferenceFebruary 26, 2024 | nasdaq.comAVITA Medical (RCEL) Price Target Increased by 6.80% to 26.69March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 26, 2024 | sg.finance.yahoo.comBRIEF-Seatrium Limited Says FY Revenue S$7.3 BlnFebruary 23, 2024 | markets.businessinsider.comAvita Medical Poised for Growth: Strong Q4 Performance and Promising 2024 Outlook Reinforce Buy RatingFebruary 23, 2024 | finance.yahoo.comAVITA Medical, Inc. (NASDAQ:RCEL) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | globenewswire.comAVITA Medical to Host Investor Webinar BriefingFebruary 23, 2024 | msn.comArdelyx Posts Q4 Loss, Joins MercadoLibre, Booking Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market SessionFebruary 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avita Medical on Strong Financials and Expansive Growth StrategyFebruary 22, 2024 | globenewswire.comAVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial GuidanceFebruary 21, 2024 | msn.comAVITA Medical Q4 2023 Earnings PreviewFebruary 17, 2024 | finance.yahoo.comRCEL Mar 2024 15.000 callFebruary 7, 2024 | finance.yahoo.comAVITA Medical, Inc. (NASDAQ:RCEL): Are Analysts Optimistic?February 1, 2024 | finance.yahoo.comAVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial ResultsJanuary 12, 2024 | markets.businessinsider.comAvita Medical Poised for Growth: Buy Rating and $40 Price Target Justified by Strategic Partnerships and Positive Financial IndicatorsJanuary 10, 2024 | finance.yahoo.comAVITA Medical Announces Exclusive Distribution Agreement with Stedical ScientificDecember 19, 2023 | seekingalpha.comAVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation MomentumNovember 20, 2023 | msn.comAvita Medical cuts 2023 commercial revenue guidance on longer hospital approval timelinesNovember 11, 2023 | markets.businessinsider.comAvita Medical Surpasses Expectations: Exploring New Markets and International Expansion with Strong Financial BackingNovember 11, 2023 | markets.businessinsider.comAvita Medical’s Promising Financial Trajectory: A Buy Rating Based on Strong Growth Indicators and Diversifying Revenue StreamsNovember 9, 2023 | benzinga.comAVITA Medical: Q3 Earnings InsightsSee More Headlines Receive RCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVITA Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:RCEL CUSIPN/A CIK1762303 Webwww.avitamedical.com Phone(833) 462-8482FaxN/AEmployees207Year Founded2008Price Target and Rating Average Stock Price Target$27.80 High Stock Price Target$40.00 Low Stock Price Target$21.00 Potential Upside/Downside+73.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,380,000.00 Net Margins-70.56% Pretax Margin-70.43% Return on Equity-54.80% Return on Assets-38.08% Debt Debt-to-Equity Ratio0.81 Current Ratio7.88 Quick Ratio7.46 Sales & Book Value Annual Sales$50.14 million Price / Sales8.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book8.35Miscellaneous Outstanding Shares25,710,000Free Float25,203,000Market Cap$412.13 million OptionableOptionable Beta1.39 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. James M. Corbett (Age 66)CEO, President & Executive Director Comp: $1.16MMr. David O'Toole (Age 65)Chief Financial Officer Comp: $574.64kMs. Donna Shiroma (Age 61)General Counsel, Chief Compliance Officer & Secretary Comp: $688.6kMr. David FencilSenior Vice President of Global OperationsDr. Katie Bush Ph.D.Senior Vice President of Scientific & Medical AffairsMs. Jessica EkebergInvestor Relations ExecutiveMs. Debbie GarnerSenior Vice President of Global Marketing & StrategyMr. Rob HallSenior Vice President of Human ResourcesMr. Terry BromleySenior Vice President of Global SalesDr. Niraj Doshi J.D.P.M.P., Ph.D., Senior Vice President of Product Development & Program ManagementMore ExecutivesKey CompetitorsBioventusNYSE:BVSSurmodicsNASDAQ:SRDXCVRxNASDAQ:CVRXAnika TherapeuticsNASDAQ:ANIKPulse BiosciencesNASDAQ:PLSEView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 32,084 shares on 3/11/2024Ownership: 5.417%Wellington Management Group LLPBought 27,881 shares on 3/5/2024Ownership: 0.108%Goldman Sachs Group Inc.Bought 5,254 shares on 3/1/2024Ownership: 0.108%Barclays PLCBought 30,143 shares on 2/15/2024Ownership: 0.135%Citadel Advisors LLCSold 14,800 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RCEL Stock Analysis - Frequently Asked Questions Should I buy or sell AVITA Medical stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVITA Medical in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCEL shares. View RCEL analyst ratings or view top-rated stocks. What is AVITA Medical's stock price target for 2024? 5 brokers have issued twelve-month price targets for AVITA Medical's shares. Their RCEL share price targets range from $21.00 to $40.00. On average, they predict the company's share price to reach $27.80 in the next year. This suggests a possible upside of 73.4% from the stock's current price. View analysts price targets for RCEL or view top-rated stocks among Wall Street analysts. How have RCEL shares performed in 2024? AVITA Medical's stock was trading at $13.72 at the beginning of 2024. Since then, RCEL shares have increased by 16.8% and is now trading at $16.03. View the best growth stocks for 2024 here. When is AVITA Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RCEL earnings forecast. How were AVITA Medical's earnings last quarter? AVITA Medical, Inc. (NASDAQ:RCEL) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The firm earned $14.20 million during the quarter, compared to analyst estimates of $14.10 million. AVITA Medical had a negative net margin of 70.56% and a negative trailing twelve-month return on equity of 54.80%. What guidance has AVITA Medical issued on next quarter's earnings? AVITA Medical issued an update on its first quarter 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.8 million-$15.6 million, compared to the consensus revenue estimate of $15.8 million. What other stocks do shareholders of AVITA Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVITA Medical investors own include NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), PayPal (PYPL), Twilio (TWLO), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Livongo Health (LVGO). Who are AVITA Medical's major shareholders? AVITA Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.45%), Vanguard Group Inc. (5.42%), Pura Vida Investments LLC (1.41%), Northern Trust Corp (0.88%), Dimensional Fund Advisors LP (0.37%) and 1492 Capital Management LLC (0.28%). Insiders that own company stock include David D O'toole, Donna Shiroma, James Corbett, Jeremy Curnock Cook, Michael S Perry, Michael S Perry and Suzanne Crowe. View institutional ownership trends. How do I buy shares of AVITA Medical? Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RCEL) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVITA Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.